GW Pharma’s Cannabis Drug fails in Cancer Study

An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study, sending shares in its British maker GW Pharmaceuticals 18 percent lower on Thursday.

GW, which is developing the drug Sativex for pain in collaboration with Japan’s Otsuka, said the first of three late-stage trials found no statistically significant difference between subjects using its product and those given a placebo.

Source: GW Pharma’s Cannabis Drug fails in Cancer Study